Trevena, Inc. (TRVN)

0,4400 +0,0230 (+5,52%) Börsenschluss: 04:00PM EDT

Trevena, Inc.

955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
https://www.trevena.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 23

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Carrie L. Bourdow	President, CEO & Chairman	1,08M	N/A	1963
Mr. Barry Shin	Executive VP, COO & CFO	722,79k	N/A	1972
Dr. Mark A. Demitrack M.D.	Senior VP & Chief Medical Officer	741,35k	N/A	1958
Dr. Howard A. Rockman M.D.	Scientific Founder, Consultant and Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Joel Solomon	VP, General Counsel, Company Secretary & Chief Compliance Officer	N/A	N/A	N/A
Mr. Michael Catalano	Vice President of Marketing	N/A	N/A	N/A
Mr. Robert T. Yoder	Senior VP, Chief Business Officer & Head of Commercial Operations	490,64k	N/A	1966
Ms. Patricia M. Drake	Senior VP & Chief Commercial Officer	N/A	N/A	1966

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Corporate Governance

Trevena, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.